Nexus Energy Services, Inc. Q3 FY2026 earnings call

• Leadership Transition: Interim Co-CEOs Kenneth Lynard and Leverne Marsh are leading the company while the board conducts a formal search for a permanent successor; strategy and pipeline remain unchanged.
• RUCONEST Stability: Returned to revenue growth with U.S. demand volume returning to prior-year levels. Over 90% of the active patient base has been retained more than one year after the launch of the first oral competitor, with particularly strong retention among high-burden patients.
• Gioenja Expansion: Achieved significant geographic expansion with launches in Germany (July) and Japan (August). The FDA approved pediatric label expansion for children aged 4–11 ahead of schedule, with shipments beginning in October.
• Pipeline Progress: Leniolisib demonstrated positive Phase II top-line data in genetic primary immunodeficiencies (PIDs), showing improvements in spleen/lymph node size and safety. Top-line data for the CVID study is expected in November.
• Napasimone Development: The pivotal Falcon study for mitochondrial disease cleared futility analysis at interim look. Enrollment is progressing well, with over 50 sites recruiting and completion expected in H1 2027.

Total revenue grew 21% year-over-year to $117.6 million. RUCONEST (Rukinest) revenue reached $93.8 million, representing an increase of 14% year-over-year and approximately 80% of total segment revenue; it benefited from stabilized underlying U.S. demand and a seasonal channel inventory buildup. Gioenja (Joengia) revenue increased 58% year-over-year to $23.8 million, contributing approximately 20% of total segment revenue, driven by strong U.S. patient growth and international expansion in Germany and Japan.

• Full-Year Revenue Guidance: Tightened to $380–$390 million, implying 1–4% growth compared to the prior year.
• Operating Expense Guidance: Lowered to $310–$315 million, reflecting 0–1% growth, which includes approximately $35 million incremental R&D investment and $9 million structural G&A savings.
• Revenue Composition Expectations: RUCONEST U.S. revenue is expected to decline approximately 3% for the full year despite Q3 stabilization. Gioenja is expected to deliver annual revenue growth in the mid-30%, outperforming the 29% growth seen in 2025.
• Gross Margin: Expected to be approximately 88% (COGS ~12%), inclusive of $10 million in manufacturing inventory impairments recorded in Q2 and Q3.

• Competitive Pressure: The introduction of new oral on-demand treatments for HAE poses ongoing competitive risks, though current data shows stable retention.
• Inventory Volatility: RUCONEST revenue performance is sensitive to seasonal channel inventory adjustments, which can fluctuate quarter-to-quarter and impact reported revenue versus underlying patient demand.
• Regulatory and Clinical Uncertainty: Future growth depends on successful regulatory approval for Gioenja’s pediatric indications and the potential expansion into CVID and other PIDs via Leniolisib, as well as the completion of the Napasimone pivotal trial.
• Leadership Transition: While currently managed by interim CEOs, the eventual selection of a permanent CEO carries inherent execution risks during the transition period.

Q: Benjamin Jackson asked about RUCONEST patient initiations in Q3 being lower than historical norms and requested details on the CEO search profile and Falcon trial recruitment speed.

A: Leverne Marsh clarified that while Q3 enrollments were seasonally soft, aggregate demand stabilized as volumes returned to prior-year levels due to strong retention (>90%) of active patients, especially high-burden cases. Kenneth Lynard stated no updates exist on the CEO search yet, emphasizing strategy remains unchanged. Dr. Anurag Relan noted that site activation was the previous bottleneck for Falcon but is now resolved, with high investigator engagement driving recent screenings.

Q: Susila Hernandez inquired about the addressable opportunity in Japan/Germany/UK, expectations for the CVID readout, and whether current cash covers pre-launch costs for KL1333.

A: Leverne Marsh declined to disclose country-specific patient counts due to early launch stages but highlighted healthy uptake in Germany and Japan, with future growth drivers including pediatric expansions and physician education. Dr. Anurag Relan explained that the CVID readout will focus on consistent direction of benefit across lymphoproliferation, cytopenias, and end-organ measures to determine the dose for Phase III. Kenneth Lynard confirmed that existing cash reserves and projected flows fully cover pipeline and pre-launch costs without need for additional financing.

Q: Joe Pantginis asked how Joenja would integrate if approved for PID/CVID indications regarding physician overlap and commercial capabilities.

A: Dr. Anurag Relan noted that APDS, CVID, and genetic PID patients are largely treated by the same group of immunologists, facilitating easy integration. Leverne Marsh added that the established U.S. commercial, medical affairs, market access, and patient services infrastructure built for Joenja/APDS is directly transferable to these new indications, allowing the company to leverage existing payer relationships and operational capabilities.